Fig. 1From: Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept studyResults for A amyloid PET SUVr and B Centiloid scale assessments from study 201 coreBack to article page